Keywords: positive, outlook, astrazeneca, recentin, azd2171, plus, folfox4

Positive outlook for AstraZeneca's Recentin

Article | 07 April 2008

Print This

AstraZeneca's Recentin (AZD2171) plus FOLFOX4 will earn a 10% patient share of the first-line stage IV colorectal cancer market in the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in